Pathology of Mucinous Appendiceal Tumors and Pseudomyxoma Peritonei

被引:56
作者
Ramaswamy V. [1 ]
机构
[1] SRL LAB, Fortis Hospital, No 154/9, Opposite IIM-B, Bannerghatta Road, Bangalore
关键词
Cytokeratin; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Immunohistochemistry; Psuedomyxoma peritonei;
D O I
10.1007/s13193-016-0516-2
中图分类号
学科分类号
摘要
Neoplasms of the appendix are rare, but because of their unusual presentation and unpredictable biologic behavior, it is important to diagnose them correctly. Mucinous tumors account for 58 % of malignant tumors of appendix in SEER database and the remaining are carcinoids. The mucinous appendiceal tumors have a potential to spread to the peritoneum and viscera in the form of gelatinous material with or without neoplastic cells resulting in Pseudomyxoma peritonei. (PMP) PMP is a clinical entity that has a unique biological behavior and can arise from seemingly benign tumors to frankly malignant ones. Several classifications exist for PMP of which Ronnet’s classification has been the most popular. In 2010, the WHO proposed a 2 tier classification that classified PMP as either low grade or high grade based on the presence of mucin, cytological and architectural features. According to this classification when the underlying cause for PMP is an appendiceal tumor it is always a mucinous adenocarcinoma rather than a mucocoele or adenoma and these terms should no longer be used. This system of classification helps in predicting the behavior of the tumor and proper treatment strategies. The understanding of the pathogenesis of the disease has also improved with identification of newer biomarkers and molecular genetic alterations. IHC markers CK 20, CDX2 and MUC2 are found to be positive in these tumors in addition to KRAS mutation and loss of heterozygosity in some gene loci. Proper histopathologic classification and predicting the tumor behavior requires a close interaction between the pathologist and the surgeon. The use of the combined modality treatment of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has led to a 5-year survival ranging from 62.5 % to 100 % for low grade, and 0 %-65 % for high grade disease. This article focuses on the etiopathogenesis, clinical behavior, diagnosis and classification of mucinous tumors of the appendix and pseudomyxoma peritonei. © 2016, Indian Association of Surgical Oncology.
引用
收藏
页码:258 / 267
页数:9
相关论文
共 70 条
[1]  
Connor S.J., Hanna G.B., Frizelle F.A., Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies, Dis Colon Rectum, 41, 1, (1998)
[2]  
Shankar S., Ledakis P., El Halabi H., Gushchin V., Sardi A., Neoplasms of the Appendix Current Treatment Guidelines, Hematol Oncol Clin N Am, 26, pp. 1261-1290, (2012)
[3]  
Kabbani W., Et al., Mucinous and nonmucinous appendiceal adenocarcinomas: Different clinicopathological features but similar genetic alterations, Mod Pathol, 15, 6, pp. 599-605, (2002)
[4]  
Muller D., Appendiceal neoplasm resulting from a malignant transformation of a villous adenoma, Chirurg, 51, 9, pp. 609-610, (1980)
[5]  
Pai R.K., Longacre T.A., Appendiceal mucinous tumors and pseudomyxoma peritonei: Histologic features diagnostic problems, and proposed classification, Adv Anat Pathol, 12, 6, pp. 291-311, (2005)
[6]  
Guo A.T., Song X., Wei L.X., Zhao P., Histological origin of pseudomyxoma peritonei in Chinese women: clinicopathology and immunohistochemistry, World J Gastroenterol, 17, pp. 3531-3537, (2011)
[7]  
Sugarbaker P.H., Are there curative options to peritoneal carcinomatosis?, Ann Surg, 242, 5, pp. 748-750, (2005)
[8]  
Sugarbaker P.H., New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?, Lancet Oncol, 7, 1, pp. 69-76, (2006)
[9]  
Gonzalez-Moreno S., Brun E., Sugarbaker P.H., Lymph node metastasis in epithelial malignancies of the appendix with peritoneal dissemination does not reduce survival in patients treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy, Ann Surg Oncol, 12, 1, pp. 72-80, (2005)
[10]  
Gonzalez-Moreno S., Sugarbaker P.H., Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding, Br J Surg, 91, 3, pp. 304-311, (2004)